Format

Send to

Choose Destination
Cancer Biomark. 2019;24(3):335-342. doi: 10.3233/CBM-181847.

Prognostic potential of the preoperative plasma complement factor B in resected pancreatic cancer: A pilot study.

Kim SH1,2, Lee MJ3,4,5, Hwang HK1,2, Lee SH1,2,6, Kim H7, Paik YK3,4,5, Kang CM1,2.

Author information

1
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, College of Medicine, Yonsei University, Seoul, Korea.
2
Pancreatobiliary Cancer Center, Yonsei Cancer Center, Severance Hospital, Seoul, Korea.
3
Yonsei Proteome Research Center, Yonsei University, Seoul, Korea.
4
Department of Integrated OMICS for Biomedical Science, Yonsei University, Seoul, Korea.
5
Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, Korea.
6
Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
7
Department of Pathology, College of Medicine, Yonsei University, Seoul, Korea.

Abstract

BACKGROUND:

For patients with pancreatic cancer, a preoperative assessment of prognosis is crucial to predict cancer recurrence and to prepare a postoperative adjuvant strategy and appropriate patient-counsel.

OBJECTIVE:

We evaluated the prognostic predictive power of complement factor B (CFB) by comparing it to that of other known tumor markers in resected pancreatic cancer patients.

METHODS:

From 2012 to 2013 period, we retrospectively reviewed the plasma CFB levels of 35 pancreatic cancer patients. The patients were divided into two groups according to serologic CFB values. Disease-free survival (DFS) and overall survival (OS) rates were analyzed.

RESULTS:

Based on the cut-off values of plasma CFB, 15 patients were placed in the low CFB group and the other 20 patients were placed in the high CFB group. There was a significant difference in DFS between the two groups (Low CFB vs. High CFB: 36.9 months vs. 13.9 months, p: 0.007). In the OS analysis, there was also a significant difference in the survival rates of the two groups (Low CFB vs. High CFB: 49.7 months vs. 29.0 months, p: 0.048).

CONCLUSION:

Preoperative plasma CFB can be used to predict the prognosis of resectable pancreatic cancers; it outperforms both CA 19-9 and CEA.

KEYWORDS:

Biomarker; complement factor B; pancreatic cancer; prognosis; survival

PMID:
30829612
DOI:
10.3233/CBM-181847
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for IOS Press
Loading ...
Support Center